Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection

Stock News

Sep 21

Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SH: 600276) has announced that its subsidiary, Suzhou Sdiary Biopharmaceuticals Co., Ltd., recently obtained the Clinical Trial Approval Notice for the SHR-4595 injection, issued by the National Medical Products Administration. The clinical trials are scheduled to commence in the near future.

The SHR-4595 injection is a therapeutic biological product independently developed by the company, designed to specifically bind to antigens on the surface of tumor cells to eliminate them, targeting the treatment of advanced malignant solid tumors. According to available data, one drug using the same target has already been approved and marketed both domestically and internationally.

As of now, the cumulative research and development investment in the SHR-4595-related projects amounts to approximately RMB 16.4 million (unaudited).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1174623645"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174623645\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174623645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 16:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174623645","market":"other","top_or_hot":-1,"title":"Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection","media":"Stock News","content":"<p><b>Jiangsu Hengrui Pharmaceuticals Co.,Ltd.</b> (SH: 600276) has announced that its subsidiary, Suzhou Sdiary Biopharmaceuticals Co., Ltd., recently obtained the Clinical Trial Approval Notice for the SHR-4595 injection, issued by the National Medical Products Administration. The clinical trials are scheduled to commence in the near future.<br><br>The SHR-4595 injection is a therapeutic biological product independently developed by the company, designed to specifically bind to antigens on the surface of tumor cells to eliminate them, targeting the treatment of advanced malignant solid tumors. According to available data, one drug using the same target has already been approved and marketed both domestically and internationally.<br><br>As of now, the cumulative research and development investment in the SHR-4595-related projects amounts to approximately RMB 16.4 million (unaudited).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-21 16:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Jiangsu Hengrui Pharmaceuticals Co.,Ltd.</b> (SH: 600276) has announced that its subsidiary, Suzhou Sdiary Biopharmaceuticals Co., Ltd., recently obtained the Clinical Trial Approval Notice for the SHR-4595 injection, issued by the National Medical Products Administration. The clinical trials are scheduled to commence in the near future.<br><br>The SHR-4595 injection is a therapeutic biological product independently developed by the company, designed to specifically bind to antigens on the surface of tumor cells to eliminate them, targeting the treatment of advanced malignant solid tumors. According to available data, one drug using the same target has already been approved and marketed both domestically and internationally.<br><br>As of now, the cumulative research and development investment in the SHR-4595-related projects amounts to approximately RMB 16.4 million (unaudited).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"","article_id":"1174623645","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174623645","pubTimestamp":1789980976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SH: 600276) has announced that its subsidiary, Suzhou Sdiary Biopharmaceuticals Co., Ltd., recently obtained the Clinical Trial Approval Notice for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0060":"抗癌","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1997245177.USD":"安联神洲A股基金","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","PSYK":"PSYK ETF","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","01276":"恒瑞医药","BMED":"iShares Health Innovation Active ETF","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","MDTX":"Corgi MediaTek 2x Daily ETF","BK0196":"行业龙头","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0239":"医药制造","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0183":"MSCI概念","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0028":"国家队","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK1191":"制药","LU0359201612.USD":"贝莱德中国基金A2"},"translate_title":"江苏恒瑞医药获得SHR-4595注射液临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"BMED":1,"IBBQ":1,"PSYK":1,"IBBJ":1,"01276":1,"MDTX":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SH: 600276) has announced that its subsidiary, Suzhou Sdiary Biopharmaceuticals Co., Ltd., recently obtained the Clinical Trial Approval Notice for the SHR-4595 injection, issued by the National Medical Products Administration. The clinical trials are scheduled to commence in the near future.The SHR-4595 injection is a therapeutic biological product independently developed by the company, designed to specifically bind to antigens on the surface of tumor cells to eliminate them, targeting the treatment of advanced malignant solid tumors. According to available data, one drug using the same target has already been approved and marketed both domestically and internationally.As of now, the cumulative research and development investment in the SHR-4595-related projects amounts to approximately RMB 16.4 million (unaudited).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}